Preop Nivoulmab Plus Chemo 'a Quantum Leap' in NSCLC Therapy

Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non–small cell lung cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/971977?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?